The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Frontline treatment of transplant eligible patients with myeloma: current approach & future changes
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the therapeutic approach used for transplant-eligible patients with multiple myeloma (MM) in the frontline setting and outlines how this may change with data from ongoing clinical trials. Findings from the PERSEUS trial (NCT03710603) suggest that the addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (VRd) induction and to lenalidomide maintenance results in improved rates of measurable residual disease (MRD)-negativity and subsequent progression-free survival (PFS). The ongoing RADAR trial (ISCRTN46841867) provides additional nuance to the treatment of this patient population through the use of genetic risk-adapted therapy and response-adapted therapy post-transplant using MRD. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
